The Filing Desk

4D Molecular Therapeutics vs MeiraGTx

4D Molecular Therapeutics FDMT · MeiraGTx MGTX · Biotechnology

4D Molecular Therapeutics reported revenue of $85 million in fiscal 2025, about the same as MeiraGTx's $81 million in fiscal 2025. 4D Molecular Therapeutics' revenue grew 230194.6% in its latest year, and MeiraGTx's grew 144.6%. 4D Molecular Therapeutics had an operating margin of -187.2%, against -130.2% at MeiraGTx. Free cash flow was −$110 million at 4D Molecular Therapeutics and −$50 million at MeiraGTx.

Side by side

4D Molecular TherapeuticsMeiraGTx
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$85M$81M
Revenue growth230,194.6%144.6%
Revenue growth a year, last 5 years44.3%39.2%
Gross margin——
Operating margin−187.2%−130.2%
Net margin−164.4%−140.3%
Free cash flow−$110M−$50M
Free cash flow margin−128.7%−61.7%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count7.4%15.2%
Last close$12.23$9.18
P/E at the last close—11.5×
Insider trades, last 12 months——
Piotroski F-score—3 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
4D Molecular TherapeuticsMeiraGTx
Operating margin
Percent of revenue
4D Molecular TherapeuticsMeiraGTx
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
4D Molecular TherapeuticsMeiraGTx

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the 4D Molecular Therapeutics and MeiraGTx pages.